Pith. sign in

REVIEW 2 major objections 1 minor 27 references

Identifying actionable driver mutations in lung cancer using an efficient Asymmetric Transformer Decoder

T0 review · 2 major / 1 minor · reviewed 2026-08-06 · deepseek-v4-flash

Challenge this review Re-run · record.json Download PDF Read on arXiv ↗

Pith's one-line read An Asymmetric Transformer Decoder predicts six actionable lung cancer driver mutations from tissue slides, beating top MIL models by 3% on average and over 4% on rare mutations.

desk verdict The abstract promises a useful clinical tool, but the submission contains no paper—only an unrelated appendix—so the 3–4% claim is uncheckable and the work isn't ready for review. read the letter →

arxiv 2508.02431 v3 pith:EUT3W6JS submitted 2025-08-04 eess.IV cs.CV

Biagio Brattoli , Jack Shi , Jongchan Park , Taebum Lee , Donggeun Yoo , Sergio Pereira This is my paper
classification eess.IVcs.CV
keywords non-smallcelllungcancerdrivermutationsmultipleinstancelearningasymmetrictransformerdecoderwhole-slideimagescomputationalpathologyweaklysupervised
verification ladder T0 review T1 audit T2 compute T3 formal

The pith

A machine-rendered reading of the paper's core claim, the machinery that carries it, and where it could break.

The reading

This paper aims to establish that a machine-learning model can read routine pathology slides and detect six actionable driver mutations in non-small cell lung cancer at once, rather than focusing on only one or two common alterations. The authors introduce an Asymmetric Transformer Decoder for multiple-instance learning (MIL), where query vectors stay low-dimensional while key and value vectors are larger, an arrangement they argue extracts information from many small image patches without overfitting. They also feed tissue-type information directly into the model, addressing a typical MIL limitation of treating all regions alike and neglecting biological relevance. The reported result is that the model outperforms top MIL models by an average of 3%, and by over 4% on rare mutations such as ERBB2 and BRAF, moving ML-based slide tests closer to practical complements to standard genetic testing.

What carries the argument

The load-bearing object is the Asymmetric Transformer Decoder, a transformer decoder in which query vectors and key/value vectors have different dimensions: the query side stays narrow while keys and values are wider. This lets the decoder process the very large number of patch embeddings in a whole-slide image at low query dimensionality, which the paper argues reduces overfitting and fits the multiple-instance learning setting naturally. The second piece of machinery is tissue-type conditioning: each patch is associated with a tissue-type label and that information is injected into the model, countering the MIL tendency to analyze all regions equally and neglecting biological relevance. The decoder's job is to turn patch embeddings into a slide-level prediction for each of the six mutations tested.

What would settle it

Train the Asymmetric Transformer Decoder on the same six-mutation task with and without tissue-type input, and evaluate both versions on an independent multi-site cohort; if the tissue-type-free version matches or beats the full model, or if the 3% average and over-4% rare-mutation margins do not reproduce, the paper's central claim is refuted.

Watch

Extended reading notes

Core claim

The central claim is that an asymmetric design for a transformer decoder makes multiple-instance learning work well for a six-way lung cancer mutation-prediction task on whole-slide images. In the model, queries use fewer dimensions than keys and values, so the decoder can interrogate a large bank of patch embeddings while keeping parameter count low and limiting overfitting. The paper further claims that supplying the model with tissue-type labels for patches gives it biological context that standard MIL approaches lack, and that these choices together improve average performance over top MIL models by 3% and rare-mutation performance by more than 4% for ERBB2 and BRAF. The intended consequence is a practical slide-based screening tool for actionable mutations in non-small cell lung cancer.

Load-bearing premise

The load-bearing premise is that reliable tissue-type labels can be assigned to every patch and that these labels do not leak the genetic-testing outcome; if tissue annotations are noisy or unavailable at deployment, the reported 3% and 4% advantages may disappear.

Editorial extensions

If this is right

  • If the results hold, slide-based screening for the full six-mutation panel becomes a realistic triage step before genetic testing, widening the pool of NSCLC patients who get mutation information.
  • The tissue-type input offers a general fix for a known MIL weakness, so it could be reused for other whole-slide biomarker prediction tasks beyond these six mutations.
  • The low-dimensional query design means the decoder can handle very large slide representations without a proportional increase in parameters, which should help it scale to bigger cohorts.
  • The larger gains on rare mutations (ERBB2 and BRAF) suggest the model is not merely re-learning common mutation patterns, but is capturing morphology that matters exactly where existing tests are weakest.

Reading between the lines

Editorial extensions of the paper, not claims the author makes directly.

  • If tissue-type annotations are what carry the improvement, the method's deployability depends on those annotations being available and accurate at inference time; a clean ablation withholding tissue-type input would settle how much of the 3% margin is architectural versus biological context.
  • The asymmetric query/key-value split is not obviously pathology-specific, so the same decoder shape could be tried in other weakly supervised tasks with enormous instance sets, such as satellite imagery or video-level prediction.
  • Because the rare-mutation gains are the largest, one testable implication is that jointly training on all six mutations shares morphology features that help rare classes; comparing the six-way model against six separately trained one-vs-rest models would isolate that multi-task benefit.
Share X Bluesky LinkedIn Reddit HN

Editorial analysis

A structured set of objections, weighed in public.

Desk editor's note, referee report, and a circularity audit.

Referee Report

2 major / 1 minor

Summary. The manuscript under review is arXiv:2508.02431 (eess.IV), titled "Identifying actionable driver mutations in lung cancer using an efficient Asymmetric Transformer Decoder." The abstract claims that a new Multiple Instance Learning (MIL) architecture, the Asymmetric Transformer Decoder, combined with a method to directly use tissue type, outperforms top MIL models by an average of 3% and by over 4% for rare mutations (ERBB2, BRAF) across six actionable NSCLC driver mutations (ALK, BRAF, EGFR, ERBB2, KRAS, MET ex14). However, the supplied full text is not the paper described in the abstract. It is an online appendix for an unrelated paper titled "AI-Based Measurement of Innovation: Mapping Expert Insight into Large Language Model Applications," containing a single figure (Figure C1) on training data distribution and a companion repository link (github.com/robi979/AI-Innovation-Measurement) that points to a different project. No model specification, tissue-type construction, dataset description, experimental protocol, cross-validation scheme, baseline identities, or result tables are present in the submission.

Significance. If the claimed results were substantiated, the paper would be a clinically relevant contribution to computational pathology, particularly because it addresses multiple actionable mutations and includes rare ones. The proposed tissue-type integration would also be a methodological novelty that could improve MIL interpretability and performance. However, the submitted manuscript provides no evidence whatsoever for these claims. The absence of the actual paper text makes any assessment of scientific significance impossible: there is no architecture to evaluate, no dataset to scrutinize, and no experimental design to check for bias or circularity. The central claim therefore remains entirely unverified.

major comments (2)
  1. [Full Text] The body of the submission is an unrelated online appendix. The title of the supplied full text is "AI-Based Measurement of Innovation: Mapping Expert Insight into Large Language Model Applications," and its companion repository (https://github.com/robi979/AI-Innovation-Measurement) is not about lung cancer, MIL, or computational pathology. None of the components needed to verify the headline claim are present: the Asymmetric Transformer Decoder architecture, the tissue-type input method, the dataset description, the cross-validation scheme, the baseline MIL models, and the per-mutation AUROC results for ALK, BRAF, EGFR, ERBB2, KRAS, and MET ex14 are all absent. This is a load-bearing omission that prevents any assessment of the paper's central claim and cannot be fixed by a local revision.
  2. [Abstract] Even taken in isolation, the abstract's quantitative claim is not backed by any experimental data in the submission. The abstract states an average 3% improvement and over 4% for ERBB2 and BRAF, but provides no confidence intervals, number of patients or whole-slide images, evaluation metric definition, baseline identities, or statistical significance. The only figure in the supplied text (Figure C1) pertains to TF-IDF and GloVe embeddings for ML classifiers in an innovation-measurement context, which is unrelated to mutation prediction. Consequently, the performance claim as stated cannot be checked or reproduced.
minor comments (1)
  1. [General] The manuscript's title and abstract are incompatible with its body; the authors should verify that the correct file was uploaded. If the submission is a placeholder or submission error, it should be corrected before any further review is attempted.

Circularity Check

0 steps flagged · score 0.0 of 10

No circularity detectable: the submission contains no derivation chain to audit.

full rationale

The abstract makes a performance claim for an Asymmetric Transformer Decoder and a tissue-type input method, but the supplied full text is an unrelated online appendix about 'AI-Based Measurement of Innovation' with a repository pointing to a different project. There are no equations, no fitted parameters, no dataset splits, no baseline comparisons, and no derivation chain in the manuscript. Circularity analysis requires the paper to exhibit a specific reduction, such as a definition that depends on the target result or a fitted input renamed as a prediction. No such reduction can be quoted because the relevant methods and results sections are absent. The mismatch between the abstract and the submitted text is a serious evidence-completeness problem, not a circularity problem: it prevents verification but does not demonstrate that any claim is equivalent to its inputs by construction. Following the hard rules, I do not manufacture circularity from a missing derivation, so the appropriate score is 0.

Assumptions & free parameters 0 free parameters · 3 assumptions · 0 invented entities

Central claims rest on tissue-image feasibility, label accuracy, and fair comparison, none of which are documented in the available text. No invented entities and no hand-fitted constants are described.

assumptions (3)
  • domain assumption H&E-stained tissue sections contain learnable visual features that correlate with six specific genomic driver mutations.
    This is the basic feasibility premise for the entire study, stated implicitly by the abstract.
  • domain assumption Genetic testing results used as labels are accurate and are matched to the same tissue sections as the images.
    If label assays are imperfect or mismatched, the reported model performance would be biased.
  • domain assumption The reported average outperformance comes from a fair comparison against named baselines with matched data splits.
    The abstract does not name baselines or splits; fair comparison is assumed for the claim to hold.

how reviews work

0 comments
Cite this review

Pith. "Pith review of Identifying actionable driver mutations in lung cancer using an efficient Asymmetric Transformer Decoder." pith.science (2026). https://pith.science/paper/EUT3W6JS

@misc{pith2026250802431,
  author       = {Pith},
  title        = {Pith review of: Identifying actionable driver mutations in lung cancer using an efficient Asymmetric Transformer Decoder},
  year         = {2026},
  howpublished = {\url{https://pith.science/paper/EUT3W6JS}},
  note         = {Machine review of arXiv:2508.02431}
}
read the original abstract

Identifying actionable driver mutations in non-small cell lung cancer (NSCLC) can impact treatment decisions and significantly improve patient outcomes. Despite guideline recommendations, broader adoption of genetic testing remains challenging due to limited availability and lengthy turnaround times. Machine Learning (ML) methods for Computational Pathology (CPath) offer a potential solution; however, research often focuses on only one or two common mutations, limiting the clinical value of these tools and the pool of patients who can benefit from them. This study evaluates various Multiple Instance Learning (MIL) techniques to detect six key actionable NSCLC driver mutations: ALK, BRAF, EGFR, ERBB2, KRAS, and MET ex14. Additionally, we introduce an Asymmetric Transformer Decoder model that employs queries and key-values of varying dimensions to maintain a low query dimensionality. This approach efficiently extracts information from patch embeddings and minimizes overfitting risks, proving highly adaptable to the MIL setting. Moreover, we present a method to directly utilize tissue type in the model, addressing a typical MIL limitation where either all regions or only some specific regions are analyzed, neglecting biological relevance. Our method outperforms top MIL models by an average of 3%, and over 4% when predicting rare mutations such as ERBB2 and BRAF, moving ML-based tests closer to being practical alternatives to standard genetic testing.

Discussion (0). Sign in to comment.

Reference graph

Works this paper leans on

27 extracted references · 24 canonical work pages

  1. [1]

    Albertina, M

    B. Albertina, M. Watson, C. Holback, R. Jarosz, S. Kirk, Y. Lee, K. Rieger-Christ, and J Lemmerman. The cancer genome atlas lung adenocarcinoma collection (tcga-luad) (version 4) [data set]. The Cancer Imaging Archive. doi: 10.7937/K9/TCIA.2016.JGNIHEP5, 2016

    work page doi:10.7937/k9/tcia.2016.jgnihep5

  2. [2]

    H&E-based Computational Biomarker Enables Universal EGFR Screening for Lung Adenocarcinoma

    Gabriele Campanella, David Ho, Ida H \"a ggstr \"o m, Anton S Becker, Jason Chang, Chad Vanderbilt, and Thomas J Fuchs. H&e-based computational biomarker enables universal egfr screening for lung adenocarcinoma. arXiv preprint arXiv:2206.10573, 2022

    work page Pith review arXiv 2022

  3. [3]

    Polydorides, Adam J

    Shengjia Chen, Gabriele Campanella, Abdulkadir Elmas, Aryeh Stock, Jennifer Zeng, Alexandros D. Polydorides, Adam J. Schoenfeld, Kuan-lin Huang, Jane Houldsworth, Chad Vanderbilt, and Thomas J. Fuchs. Benchmarking embedding aggregation methods in computational pathology: A clinical data perspective. Proceedings of the MICCAI Workshop on Computational Path...

    work page 2024

  4. [4]

    Circulating tumor cell detection technologies and clinical utility: Challenges and opportunities

    Zeina Habli, Walid AlChamaa, Raya Saab, Humam Kadara, and Massoud L Khraiche. Circulating tumor cell detection technologies and clinical utility: Challenges and opportunities. Cancers, 12 0 (7), 2020

    work page 2020

  5. [5]

    The biology and management of non-small cell lung cancer

    Roy S Herbst, Daniel Morgensztern, and Chris Boshoff. The biology and management of non-small cell lung cancer. Nature, 553 0 (7689): 0 446--454, 2018

    work page 2018

  6. [6]

    Attention-based deep multiple instance learning

    Maximilian Ilse, Jakub Tomczak, and Max Welling. Attention-based deep multiple instance learning. International conference on machine learning, 2018

    work page 2018

  7. [7]

    Benchmarking self-supervised learning on diverse pathology datasets

    Mingu Kang, Heon Song, Seonwook Park, Donggeun Yoo, and Sérgio Pereira. Benchmarking self-supervised learning on diverse pathology datasets. Proceedings of the IEEE/CVF Conference on Computer Vision and Pattern Recognition (CVPR), June 2023

    work page 2023

  8. [8]

    S. Kirk, Y. Lee, P. Kumar, J. Filippini, B. Albertina, M. Watson, K. Rieger-Christ, and J Lemmerman. The cancer genome atlas lung squamous cell carcinoma collection (tcga-lusc) (version 4) [data set]. The Cancer Imaging Archive. doi: 10.7937/K9/TCIA.2016.TYGKKFMQ, 2016

    work page doi:10.7937/k9/tcia.2016.tygkkfmq

Show all 27 references
  1. [9]

    Dynamic graph representation with knowledge-aware attention for histopathology whole slide image analysis

    Jiawen Li, Yuxuan Chen, Hongbo Chu, Qiehe Sun, Tian Guan, Anjia Han, and Yonghong He. Dynamic graph representation with knowledge-aware attention for histopathology whole slide image analysis. Proceedings of the IEEE/CVF Conference on Computer Vision and Pattern Recognition (C...

    2024

  2. [10]

    Semantics-aware attention guidance for diagnosing whole slide images

    Kechun Liu, Wenjun Wu, Joann G Elmore, and Linda G Shapiro. Semantics-aware attention guidance for diagnosing whole slide images. International Conference on Medical Image Computing and Computer-Assisted Intervention (MICCAI), 2024

    2024

  3. [11]

    Cury, Taiga Abe, Venkatesh N

    Alexander Mathis, Pranav Mamidanna, Kevin M. Cury, Taiga Abe, Venkatesh N. Murthy, Mackenzie W. Mathis, and Matthias Bethge. Deeplabcut: markerless pose estimation of user-defined body parts with deep learning. Nature Neuroscience, 2018

    2018

  4. [12]

    Lung cancer ldct screening and mortality reduction—evidence, pitfalls and future perspectives

    Matthijs Oudkerk, ShiYuan Liu, Marjolein A Heuvelmans, Joan E Walter, and John K Field. Lung cancer ldct screening and mortality reduction—evidence, pitfalls and future perspectives. Nature reviews Clinical oncology, 18 0 (3): 0 135--151, 2021

    2021

  5. [13]

    Predicting egfr mutational status from pathology images using a real-world dataset

    James J Pao, Mikayla Biggs, Daniel Duncan, Douglas I Lin, Richard Davis, Richard SP Huang, Donna Ferguson, Tyler Janovitz, Matthew C Hiemenz, Nathanial R Eddy, et al. Predicting egfr mutational status from pathology images using a real-world dataset. Scientific reports, 13 0 (1), 2023

    2023

  6. [14]

    Metastatic non-small cell lung cancer: Esmo clinical practice guidelines for diagnosis, treatment and follow-up

    D Planchard, ST Popat, K Kerr, S Novello, EF Smit, Corinne Faivre-Finn, TS Mok, M Reck, PE Van Schil, MD Hellmann, et al. Metastatic non-small cell lung cancer: Esmo clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 29, 2018

    2018

  7. [15]

    U-net: Convolutional networks for biomedical image segmentation

    Olaf Ronneberger, Philipp Fischer, and Thomas Brox. U-net: Convolutional networks for biomedical image segmentation. International Conference on Medical Image Computing and Computer-Assisted Intervention (MICCAI), pages 234--241, 2015

    2015

  8. [16]

    H-optimus-0, 2024

    Charlie Saillard, Rodolphe Jenatton, Felipe Llinares-López, Zelda Mariet, David Cahané, Eric Durand, and Jean-Philippe Vert. H-optimus-0, 2024. URL https://github.com/bioptimus/releases/tree/main/models/h-optimus/v0

    2024

  9. [17]

    Transmil: Transformer based correlated multiple instance learning for whole slide image classification

    Zhuchen Shao, Hao Bian, Yang Chen, Yifeng Wang, Jian Zhang, Xiangyang Ji, et al. Transmil: Transformer based correlated multiple instance learning for whole slide image classification. Advances in neural information processing systems, 34, 2021

    2021

  10. [18]

    Vila-mil: Dual-scale vision-language multiple instance learning for whole slide image classification

    Jiangbo Shi, Chen Li, Tieliang Gong, Yefeng Zheng, and Huazhu Fu. Vila-mil: Dual-scale vision-language multiple instance learning for whole slide image classification. Proceedings of the IEEE/CVF Conference on Computer Vision and Pattern Recognition, 2024 a

    2024

  11. [19]

    Integrative graph-transformer framework for histopathology whole slide image representation and classification

    Zhan Shi, Jingwei Zhang, Jun Kong, and Fusheng Wang. Integrative graph-transformer framework for histopathology whole slide image representation and classification. International Conference on Medical Image Computing and Computer-Assisted Intervention (MICCAI), 2024 b

    2024

  12. [20]

    Artificial intelligence in histopathology: enhancing cancer research and clinical oncology

    Artem Shmatko, Narmin Ghaffari Laleh, Moritz Gerstung, and Jakob Nikolas Kather. Artificial intelligence in histopathology: enhancing cancer research and clinical oncology. Nature cancer, 3 0 (9), 2022

    2022

  13. [21]

    Attention is all you need

    Ashish Vaswani, Noam Shazeer, Niki Parmar, Jakob Uszkoreit, Llion Jones, Aidan N Gomez, ukasz Kaiser, and Illia Polosukhin. Attention is all you need. Advances in neural information processing systems, 30, 2017

    2017

  14. [22]

    Celina Villa, Philip T Cagle, Melissa Johnson, Jyoti D Patel, Anjana V Yeldandi, Rishi Raj, Malcolm M DeCamp, and Kirtee Raparia. Correlation of egfr mutation status with predominant histologic subtype of adenocarcinoma according to the new lung adenocarcinoma classification o...

    2014

  15. [23]

    Transformer-based biomarker prediction from colorectal cancer histology: A large-scale multicentric study

    Sophia J Wagner, Daniel Reisenb \"u chler, Nicholas P West, Jan Moritz Niehues, Jiefu Zhu, Sebastian Foersch, Gregory Patrick Veldhuizen, Philip Quirke, Heike I Grabsch, Piet A van den Brandt, et al. Transformer-based biomarker prediction from colorectal cancer histology: A la...

    2023

  16. [24]

    Mambamil: Enhancing long sequence modeling with sequence reordering in computational pathology

    Shu Yang, Yihui Wang, and Hao Chen. Mambamil: Enhancing long sequence modeling with sequence reordering in computational pathology. International Conference on Medical Image Computing and Computer-Assisted Intervention (MICCAI), 2024

    2024

  17. [25]

    Exaonepath 1.0 patch-level foundation model for pathology

    Juseung Yun, Yi Hu, Jinhyung Kim, Jongseong Jang, and Soonyoung Lee. Exaonepath 1.0 patch-level foundation model for pathology. arXiv preprint arXiv:2408.00380, 2024

    2024 arXiv

  18. [26]

    Dynamic policy-driven adaptive multi-instance learning for whole slide image classification

    Tingting Zheng, Kui Jiang, and Hongxun Yao. Dynamic policy-driven adaptive multi-instance learning for whole slide image classification. Proceedings of the IEEE/CVF Conference on Computer Vision and Pattern Recognition (CVPR), June 2024

    2024

  19. [27]

    A graph-transformer for whole slide image classification

    Yi Zheng, Rushin H Gindra, Emily J Green, Eric J Burks, Margrit Betke, Jennifer E Beane, and Vijaya B Kolachalama. A graph-transformer for whole slide image classification. IEEE transactions on medical imaging, 41 0 (11), 2022

    2022

Pith tools

Reviewed August 6, 2026 · model on record in the stance chip above.